Eczemol

Manufacturer
PLYMOUTH HEALTHCARE PRODUCTS LLC
Effective date
2025-11-20
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
10
Source
full-release
Hydrated at
2026-06-01 02:35:18

Label at a glance#

ProductEczemol
Active ingredientPOTASSIUM BROMIDE, NICKEL SULFATE, SULFUR
Label structure14 sections

Dosage and administration

Absorption of nickel sulphate is variable among individuals. For maximum absorption, tablets should be taken orally at the beginning of the day (or any convenient time after having taken nothing but water for at least 7 hours). Take nothing but water for one hour after taking medication to aid absorption. Kg lbs Starting dose Max Daily dose 5-11 11-25 ¼ ½ 12-22 26-50 ½ 1 23-45 51-100 1 2 46-68 101-150 2 4 69-90 15...

Label contents#

Full prescribing information#

CAUTION

SPL UNCLASSIFIED SECTION

Federal law prohibits dispensing without a prescription.

DESCRIPTION

DESCRIPTION SECTION

ECZEMOL ®is a biochemical homeopathic medication indicated for the treatment of eczema. 27,29The active ingredients in each ECZEMOL ®tablet consist of the following: Potassium Bromide (Kali Bromatum) 1X, Sulphur 1X, and Nickel Sulphate (Niccolum Sulphuricum) 1X. These drug ingredients are listed in the Homoeopathic Pharmacopoeia of the United States (HPUS). 1

Inactive ingredients: Lactose, Fumaric Acid, and Magnesium Stearate.

Pharmacological class:Homeopathic drug.

Dosage form:Oral 300 mg scored tablet. May be swallowed whole, chewed or dissolved in the mouth and swallowed.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The active ingredients in ECZEMOL ®are simple biochemical compounds. The exact mechanism of action is unknown; however, it is believed ECZEMOL ®addresses a primary genetic biochemical defect.

POTASSIUM BROMIDEdissolves and dissociates in the digestive tract into its ionic constituents. Each tablet contains approximately 15 mg of bromide (calculated). Ionic bromide is rapidly and completely absorbed from the intestine and distributed almost exclusively in the extracellular fluids. 7,8Bromide is eliminated by the kidneys and the elimination half-life is 11-12 days. "Once a day" dosing will lead to a steady state concentration in about seven weeks. 7

SULPHURis a naturally occurring mineral that is an essential part of the human body. It exhibits anti-bacterial, anti-parasitic, fungicidal, and keratolytic properties. 26Each tablet contains approximately 1.5 mg of sulphur (calculated). Sulphur is highly water soluble and as a result is easily excreted by the body via sweat and urine. 22Since the sulphur found in ECZEMOL ®is a naturally occurring mineral, it is radically different from sulfa drugs (sulfonamide antibiotics). Therefore, patients who are allergic to sulfa drugs CAN safely take ECZEMOL ® .

NICKEL SULPHATEdissolves and dissociates in the digestive tract into its ionic constituents. Each tablet contains approximately 0.5 mg of ionic nickel (calculated). According to studies, 15% to 50% of ionic nickel is absorbed on a fasted stomach. 2Food markedly decreases the rate and extent of nickel absorption. 3,4Clinical studies show that serum concentrations of nickel are variable among patients after administering the same dosage. 5Peak serum nickel concentration is reached about two hours after oral administration. "Once a day" dosing leads to steady state serum concentrations in approximately one week. Nickel is in its highly stable divalent cation state and is therefore not expected to be metabolized to any significant degree in the body. Absorbed nickel is primarily excreted in the urine and elimination half-life is about 21 hours. 3,5Renal clearance is rapid and efficient, and nickel does not accumulate in the body. 6

CLINICAL STUDIES

CLINICAL STUDIES SECTION

A variety of controlled clinical studies have been performed using various sources of both nickel and bromide in over 300 subjects. Clinical efficacy and safety have been documented in a significant number of subjects. Published and unpublished reports are available upon request. 9,20,21

INDICATIONS

INDICATIONS & USAGE SECTION

ECZEMOL ®is indicated for the treatment of moderate to severe eczema and atopic dermatitis. It has been found to work well with a variety of combination therapies.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Although there are no known contraindications, patients who are allergic to any ECZEMOL ®ingredient should consult a physician prior to taking the medication. (Refer to Section on Hypersensitivity)

WARNING

WARNINGS SECTION

Do not use if imprinted seal under bottle cap is missing or broken. Do not use if pregnant or nursing. If allergic to nickel or metal objects such as jewelry or if there is a history of blistering hand eczema, see PRECAUTIONSfor hypersensitivity information. Lactose intolerant patients may have gastrointestinal difficulty. This has very rarely been reported at the doses used.

PRECAUTIONS

PRECAUTIONS SECTION

Carefully adjust dosage to weight when treating young children. Use cautiously in setting of kidney disease. (see Dosage and Administration) If skin rash appears or if nervous symptoms persist, recur frequently, or are unusual, discontinue use.

Hypersensitivity

SPL UNCLASSIFIED SECTION

Caution should be used when administering to patients with a history of contact sensitivity to nickel (common metal exposure) or if there is a history of vesicular hand eczema (dyshidrosis, pomphylox). Nickel allergy may be confirmed by a positive nickel patch test. Most patients with hand eczema, positive nickel allergy history, or a positive nickel patch test do nothave any untoward reaction to administration of ECZEMOL ®. If there is a history of nickel sensitivity or dyshidrotic hand eczema, begin with a very low dose and slowly increase to a recommended starting dose over a period of 5 weeks as tolerated, thus allowing progressive GI absorption *.

*Nickel desensitization schedule:
WeekAmount of Time to Take
Medication Prior to Breakfast
Week 1With Breakfast
Week 215 min Prior
Week 330 min Prior
Week 445 min Prior
Week 5 and thereon1 hour Prior

If new pruritic rashes occur or persist, discontinue ECZEMOL ®and treat appropriately. Do not use if there is a history of extra-cutaneous hypersensitivity to nickel or any ingredient in ECZEMOL ®.

Information for patients

INFORMATION FOR PATIENTS SECTION

Patients using ECZEMOL ®should receive the following information and instructions:

  1. This medication is to be used as directed by a physician.
  2. It is important to take orally at the beginning of the day on an empty stomach (or any convenient time after having taken nothing but water for at least 7 hours) and to eat or drink nothing but water for at least one hour afterwards to avoid interference with absorption.

Drug interactions

DRUG INTERACTIONS SECTION

There are no known drug interactions.

Carcinogenesis, mutagenesis, impairment of fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No studies have been done on the carcinogenesis, mutagenesis, or impairment of fertility of ECZEMOL ®. No carcinogenesis or mutagenesis has been reported in multiple animal studies for oral administration of soluble nickel and bromide salts (active ingredients) even at very high doses. 10-14

Effects of soluble potassium bromide

SPL UNCLASSIFIED SECTION

KBr is not listed as a carcinogen by the NTP, IARC, and OSHA. 16

Effects of sulphur

SPL UNCLASSIFIED SECTION

Sulphur is not listed as a carcinogen by the ACGIH, IARC, NIOSH, NTP, or OSHA. 25

Effects of soluble nickel sulphate

SPL UNCLASSIFIED SECTION

Studies on experimental animals have never indicated that nickel, at any dose, is a carcinogen when introduced to the body orally. Furthermore, Nickel sulphate and other highly water soluble nickel salts, have never been known to induce carcinogenesis via any route of introduction including: oral, inhalation, cutaneous, IM, or IP. 10-12,15No adverse effects were noted on fertility or reproduction in a 3-generational study of albino Wistar rats fed up to 1000 ppm Ni per day, which is equivalent to 50 mg/kg body weight per day Ni. 15

Pregnancy

PREGNANCY SECTION

Pregnancy category C

TERATOGENIC EFFECTS SECTION

Animal reproduction studies have not been conducted with ECZEMOL ®. ECZEMOL ®should not be given to a pregnant woman.

Nursing mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. However, since many drugs are excreted in human milk, caution should be exercised when ECZEMOL ®is administered to a nursing woman.

Pediatric use

PEDIATRIC USE SECTION

Carefully adjust dosage to weight when treating young children.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

ECZEMOL ®contains low doses of active ingredients. Therefore there are minimal known side effects. (see PRECAUTIONSfor hypersensitivity information)

OVERDOSAGE

OVERDOSAGE SECTION

Potassium bromide toxicity

SPL UNCLASSIFIED SECTION

Indications of toxicity due to oral overdosage of bromide may include nausea, vomiting, apathy, disturbed coordination, loss of memory, drowsiness, loss of emotional control, agitation, hallucination, tremors, depressed reflexes, stupor, and coma. Acute toxic reactions in humans have been reported at doses as low as 1000 mg. 19This level is 67 times the dose received in one tablet of ECZEMOL ®.

Sulphur toxicity

SPL UNCLASSIFIED SECTION

The oral rat LD 50for sulphur is reported to be greater than 5,000 mg/kg . 23This is more than 37,000 times the maximum dose recommended for ECZEMOL ®. (see Dosage) Ingestion of toxic levels of sulphur can cause sore throat, nausea, headache, gastrointestinal irritation, and possibly unconsciousness in severe cases. 24,25Sulphur poses such a remote risk that it is placed in the lowest toxic category possible, EPA Toxicity Category IV. 23

Nickel sulphate toxicity

SPL UNCLASSIFIED SECTION

The oral rat LD 50for nickel sulphate hexahydrate is 275 mg/kg. 17Symptoms of toxicity due to oral overdosage of nickel sulphate may include nausea, vomiting, abdominal discomfort, diarrhea, giddiness, lassitude, headaches, cough, and shortness of breath. 18The lowest observed transitory toxic effects from human ingestion of soluble nickel salts is approximately 8 mg nickel/kg body weight. 18This is 180 times the maximum dose recommended for ECZEMOL ®. (See below)

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Absorption of nickel sulphate is variable among individuals. For maximum absorption, tablets should be taken orally at the beginning of the day(or any convenient time after having taken nothing but water for at least 7 hours). Take nothing but water for one hour after taking medication to aid absorption.

KglbsStarting
dose
Max Daily dose
5-1111-25¼½
12-2226-50½1
23-4551-10012
46-68101-15024
69-90151-20036
91+201+48

In the setting of renal impairment

SPL UNCLASSIFIED SECTION

Dosage should be adjusted and serum nickel and bromide levels should be followed. Steady state trough level should be drawn prior to ingesting the day's dose after one week of dosing or at appropriate intervals. Target trough serum nickel level is 20-40 mcg/L. (Caution: post dose peak levels are unreliable.) Treatment duration depends on the individual. Increase dose as needed on a monthly basis. Try b.i.d. dosing (upon rising and at bedtime) if max dose (see above) is not effective; do not exceed max daily dose.

Maintenance phase

SPL UNCLASSIFIED SECTION

In order to maintain symptomatic relief, medication may be continued at the same or reduced initial phase dose level.

HOW SUPPLIED

HOW SUPPLIED SECTION

Scored tablets, off white in color with green speckles, with SymbolSymbol and scoreimprinted on same side, in child-resistant and tamper-resistant bottles of 100. NDC 61480-127-05

SPL UNCLASSIFIED SECTION

RxSales@PlymouthPharmaceuticals.com

www.PlymouthPharmaceuticals.com

Plymouth Pharmaceuticals Inc. dba LOMA LUX Laboratories; P.O. BOX 702418; Tulsa, OK 74170-2418

Phone 800.316.9636, 918.664.9882, Fax 918.664.9884

Revised 2.7.06 mn

PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 61480-127-05
Homeopathic Medication

ECZEMOL ®

Indicated for treatment of
ECZEMA

100 Tablets

PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label
PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeEAN-130361480127053GTIN-13: 0361480127053
EAN-13: 0361480127053
GTIN-12: 361480127053
UPC-A: 361480127053
GTIN storage (14 digits): 00361480127053
eczemol-02.jpg

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
61480-127-05Eczemol100 in 1 BOTTLETABLET10010

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
61480-127-05EA - Each61480-1276a53584a-de55-4b00-aaa7-aa785a70cd3612015-10-02

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
Nickel SulfateACTIVE INGREDIENT4FLT4T3WUN3
Potassium BromideACTIVE INGREDIENTOSD78555ZM3
SulfurACTIVE INGREDIENT70FD1KFU703
BROMIDE IONACTIVE MOIETY952902IX063
NICKEL CATIONACTIVE MOIETYOIS2CXW7AM3
SulfurACTIVE MOIETY70FD1KFU703

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
61480-12761480-127-05

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 3 matching rows.

Name, UNII, Kind table
NameUNIIKind
POTASSIUM BROMIDEOSD78555ZMACTIB
NICKEL SULFATE4FLT4T3WUNACTIB
SULFUR70FD1KFU70ACTIB

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
EczemolPOTASSIUM BROMIDE, NICKEL SULFATE, AND SULFURPLYMOUTH HEALTHCARE PRODUCTS LLC981e9f3d-b608-4a5e-92f8-895b22da12f42025-11-20Warnings, Adverse reactionsExact identifier
ndc (package): 61480-127-05
ndc (product): 61480-127
ndc11 (package): 61480012705
spl id: 440c8a06-8ffb-f7af-e063-6394a90a7ccf
spl set id: 981e9f3d-b608-4a5e-92f8-895b22da12f4

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.